Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.
about
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Melanoma: From Incurable Beast to a Curable Bet. The Success of ImmunotherapyClinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialAbscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.Melanoma of the oral cavity: pathogenesis, dermoscopy, clinical features, staging and management.Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy.Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review.Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.Update on primary head and neck mucosal melanoma.Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses.Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programmeInterleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma.Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.What have we learned from cancer immunotherapy in the last 3 years?Treatment of Primary and Metastatic Multifocal Mucosal Melanoma of the Oral Cavity with ImatinibWhole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.Association of Surgical Approach and Margin Status With Oncologic Outcomes Following Gross Total Resection for Sinonasal Melanoma.Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas.Current and future immunotherapies for thyroid cancer.Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial.Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy.Anorectal mucosal melanoma.Efficacy of immunotherapy for metastatic mucosal melanoma.Immunotherapy in mucosal melanoma: a case report and review of the literature.Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?
P2860
Q26770492-8EC91F89-38E3-40AC-A2F5-55385BDBB142Q26798404-33F2C68F-BD64-405D-B930-41E451E2D211Q30828178-25C4A366-C7ED-443E-B7D2-7B8D1456753EQ33749057-8AF36D02-5727-45E0-A417-434510F32B78Q33930593-3589BAD0-7235-42E9-A3AA-62C48FB4D526Q34331179-E6674EA3-238C-4BD0-9365-188D6C8452BCQ34613585-834BC796-D48E-4D8F-B946-7ABEEF8CCF08Q35798996-25886432-3EEC-4397-BC22-87F587AEA7CAQ36064844-2FBEB1D4-E700-4E99-BFAB-9E057388EDF5Q36256712-F6F76A0C-3A34-486B-8582-143583258EE4Q37178922-9E3A856A-DEC1-4410-A5C7-A071D4301656Q37577095-000A00EE-9E14-43CB-8EAA-AF18834E9079Q37582623-F347DC9C-E67B-4E2A-B47A-2AAEFD2695C6Q37606693-20CDF661-B861-4C65-872C-554A08E1710EQ37718203-4F18EA7B-FF48-4843-A827-B253D7DC369CQ38595251-6F403E15-294F-4D02-BC3B-6B0663621797Q39038191-4A219EEC-D9C3-43AC-A0A8-AA9558C82054Q40065733-8756770C-8F6F-4E11-8A6C-D775AB76BFF4Q41488462-6784867A-D31A-4FBF-A83D-448120454C8AQ42338844-D10858A2-2DCE-46E4-942B-B51DC6EA2B78Q42697894-81068232-E091-4012-BBF7-60B3AF4EA530Q47547587-AD052CA9-2CC3-4523-98F4-722D2D44044BQ47781457-6BE62A2A-42E4-4A8A-8299-6AA2BB732057Q51529309-2459E642-F401-4CD0-8FFC-FF1C0AA7DD17Q52657766-C7700B8C-C00A-4E72-A57A-4F5FBCBF9458Q52680468-71F68F34-9889-4F60-85E8-9AEA3D32EE7AQ53072770-AA71A94B-B1D9-4AC3-A38F-E48E7B2F73A6Q55053720-6FF86BD2-EB07-4A59-8349-C91A720C540BQ57166568-CC001EA2-2231-4B0F-8768-F42EEFFE0BC3
P2860
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Efficacy and safety of ipilimu ...... metastatic, mucosal melanoma.
@ast
Efficacy and safety of ipilimu ...... metastatic, mucosal melanoma.
@en
Efficacy and safety of ipilimu ...... metastatic, mucosal melanoma.
@nl
type
label
Efficacy and safety of ipilimu ...... metastatic, mucosal melanoma.
@ast
Efficacy and safety of ipilimu ...... metastatic, mucosal melanoma.
@en
Efficacy and safety of ipilimu ...... metastatic, mucosal melanoma.
@nl
prefLabel
Efficacy and safety of ipilimu ...... metastatic, mucosal melanoma.
@ast
Efficacy and safety of ipilimu ...... metastatic, mucosal melanoma.
@en
Efficacy and safety of ipilimu ...... metastatic, mucosal melanoma.
@nl
P2093
P50
P1476
Efficacy and safety of ipilimu ...... metastatic, mucosal melanoma.
@en
P2093
Carmen Nuzzo
Elena Tornari
Federica De Galitiis
Gaetana Rinaldi
Paolo A Ascierto
Riccardo Marconcini
Vanna Chiarion Sileni
P304
P356
10.1016/J.EJCA.2013.09.007
P50
P577
2013-10-04T00:00:00Z